NORMOXYS
NormOxys, Inc. operates as a biopharmaceutical company. It provides proprietary products that regulate the binding affinity between oxygen and hemoglobin. NormOxys, Inc. was formerly known as Oxyplus, Inc. and changed its name to NormOxys, Inc. in October 2008. The company was founded in 2003.
NORMOXYS
Industry:
Biotechnology Health Care Medical
Founded:
2003-01-01
Address:
Wellesley, Massachusetts, United States
Country:
United States
Website Url:
http://www.normoxys.com
Total Employee:
11+
Status:
Active
Contact:
781-391-0770
Email Addresses:
[email protected]
Total Funding:
30.46 M USD
Technology used in webpage:
Google Analytics Apache Google Analytics Classic Unified Layer CentOS Apache 2.2 BlueHost
Similar Organizations
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Current Employees Featured
Founder
Investors List
Index Ventures
Index Ventures investment in Series B - NormOxys
Care Capital
Care Capital investment in Series B - NormOxys
Droia Ventures
Droia Ventures investment in Venture Round - NormOxys
Official Site Inspections
http://www.normoxys.com
- Host name: 208.91.197.132
- IP address: 208.91.197.132
- Location: British Virgin Islands
- Latitude: 18.5
- Longitude: -64.5
- Timezone: America/Tortola
More informations about "NormOxys"
NormOxys - Crunchbase Company Profile & Funding
NormOxys is a biotechnology company developing a new class of polyol phosphate-based small molecule drugs for the treatments of cancers. NormOxys, Inc. operates as a …See details»
NormOxys Company Profile 2024: Valuation, Funding …
Information on valuation, funding, cap tables, investors, and executives for NormOxys. Use the PitchBook Platform to explore the full profile.See details»
NormOxys - VentureRadar
NormOxys is a biopharmaceutical company headquartered in Boston, MA with laboratories in Boston and Strasbourg, France. NormOxys has discovered and is currently developing a novel …See details»
Normoxys, Inc. Company Profile | Medford, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Normoxys, Inc. of Medford, MA. Get the latest business insights from Dun & Bradstreet.See details»
NormOxys Inc - Company Profile and News - Bloomberg Markets
NormOxys, Inc. operates as a biopharmaceutical company. The Company offers products for the treatment of heart failure, diabetic retinopathy, cancer, and traumatic blood loss.See details»
NormOxys - Company Profile - Tracxn
Nov 6, 2024 · NormOxys - Developing polyol phosphate-based small molecule drugs for the treatments of cancers. Raised a total funding of $24.2M over 5 rounds from 2 investors. …See details»
NormOxys - Products, Competitors, Financials, Employees, …
NormOxys has discovered and is currently developing a proprietary technology platform that generates a class of small molecule drugs, oxyrens, which enhance the body's ability to …See details»
NormOxys - Funding, Financials, Valuation & Investors - Crunchbase
NormOxys is a biotechnology company developing a new class of polyol phosphate-based small molecule drugs for the treatments of cancers.See details»
NormOxys Appoints Industry Veteran and Recognized …
Dec 4, 2009 · NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today …See details»
NormOxys Inc. - BioCentury Company Profiles - BCIQ
Historical deals and financings can be found by searching the organization's name in the BCIQ Deals and Financing Modules.See details»
NormOxys Inc. :: HBW Insight
Jun 1, 2010 · NormOxys is betting that its lead candidate can help elevate oxygen levels in human tissues that lack it, and so become a treatment for a range of disorders, from heart …See details»
NormOxys - Contacts, Employees, Board Members, Advisors
NormOxys has 2 current employee profiles, including CSO, Founder Claude Nicolau. NormOxys is a biotechnology company developing a new class of polyol phosphate-based small molecule …See details»
NormOxys appoints CEO, explores oxyrens | Fierce Biotech
Dec 4, 2009 · Founded in 2004, biotech start-up NormOxys is talking for the first time today about programs, plans and a new CEO. The company has appointed Martin Tolar as its chief.See details»
NormOxys gets $17.5M to fund PoC work on new drug class
May 24, 2010 · NormOxys is working on a new class of therapeutics-dubbed oxyrens-which essentially restores the needed level of oxygen in diseased "hypoxic tissues." Anyone familiar …See details»
NormOxys Secures $17.5M and Takes Lead Oxygen Release …
May 24, 2010 · NormOxys raised $17.5 million in Series B financing for clinical development of its lead drug candidate, OXY111A, as a treatment for both chronic heart failure and cancer.See details»
NormOxys - Tech Stack, Apps, Patents & Trademarks - Crunchbase
NormOxys is a biotechnology company developing a new class of polyol phosphate-based small molecule drugs for the treatments of cancers.See details»
Research programme: oxygen release enhancers - NormOxys Inc.
NormOxys Inc. is developing small molecule, allosteric effectors of haemoglobin known as oxygen release enhancers, or 'oxyrens', for the treatment of hypoxiaSee details»
NormOxys Secures $17.5 Million Series B Financing to Advance …
May 24, 2010 · WELLESLEY, Mass.-- (EON: Enhanced Online News)--NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the …See details»
NormOxys, Inc. Initiates Phase 1 Clinical Trial of ... - BioSpace
May 24, 2010 · NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications. The Phase 1 trial will evaluate OXY111A in healthy …See details»
Development of OXY111A, a novel hypoxia-modifier as a potential ...
Oct 19, 2016 · OXY111A is a synthetic allosteric effector of hemoglobin 4. OXY111A is taken up by red blood cells via the band 3.1 transporter and promotes the dissociation of oxygen from …See details»